the basis of T/R in the Pro­tocol [Regulatives / Guidelines]

posted by mittyri  – Russia, 2014-03-14 22:08 (4130 d 11:39 ago) – Posting: # 12631
Views: 7,497

Dear Helmut,

Thank you for the inestimable contribution to my (and others) knowledge in BEQ :cool:

❝ By “pilot” I meant studies the sponsor performed or have access to in an acquired dossier. Only such studies can be assesses for the quality of data (clinical performance, bioanalytics, …).


If I understand right, you state in the protocol phrases like that:
According to the earlier performed by sponsor study, T/R ratio could be assumed as 0.92%.
How could I prove to the assessor that "pilot" study is really performed? As a sponsor I can write that I performed the study in another market, but assessment report isn't published (no links)

❝ Once the Austrian agency AGES did not like the sample size we stated in the protocol: “It is not acceptable to perform the study in only 16 sub­jects when most of the BE studies of XYZ are performed in more than 30.” Hey, it was a pilot study… Case closed. :-D


Nice example :-D
In this case, did you "hit the jackpot" (by the luck CI's were in the borders)?

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,684 registered users;
36 visitors (0 registered, 36 guests [including 23 identified bots]).
Forum time: 10:47 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5